| Description |
Interferon β-1b, a stable analog of human interferon-βproduced by recombinant DNA technique, is the first biotechnology product to be licensed under the FDA's accelerated approval regulation. It is the first drug available for the treatment of relapsing remitting multiple sclerosis (MS). The mechanism of action of interferon β-1b in MS remains unknown. It has shown immunoregulatory properties including its ability to decrease T-cell proliferation, to block the synthesis of interferonγthat may be involved in MS, to inhibit release of other cytokines that damage oligodendrocytes, and to increase T suppresser-cell activity. Interferonβ-1b has also demonstrated potential in melanoma, renal cell carcinoma, genital warts, hepatitis, rhinovirus, and several types of malignant tumors.
|
